Type 2 Diabetes Mellitus - Frontier Pharma - GPCRs and Protein Kinases Dominate Pipeline

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases. Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy. The emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm. In spite of these developments, there are still significant unmet needs for T2DM, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the large T2DM pipeline, with a diverse range of first-in-class targets identified. Scope The escalating T2DM public healthcare need has resulted in a competitive market landscape

• What is the pathophysiology of T2DM?
• What are the common co-morbidities and complications?
• How has the emergence of new drug classes in the past decade impacted the treatment algorithm? 
• What are the most significant unmet needs within the market? 

• Which molecule types and molecular targets are most prominent within the pipeline? 
• Which first-in-class targets are most promising? 
• How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class? 

• Do T2DM products attract high deal values? 
• Which molecule types and molecular targets dominate the deals landscape? 
• Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

• Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options. 
• Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.